Loading...
The FDA has favorably reviewed the hepatitis C virus (HCV) protease inhibitors boceprevir and telaprevir, opening the door to a new era of HCV treatment. Should patients with stable disease act now or wait for better options? How will clinicians choose between the two drugs? And which providers should be leading HCV management anyway — gastroenterologists or ID docs? In his blog HIV and ID Observations, Dr. Paul Sax explores these and other “known unknowns” of HCV treatment.